Obesitas pharmacokinetics and pharmacodynamics of propofol and nadroparin in morbidly obese patients
Conditions
Interventions
None listed
Sponsors
Sint Antonius Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 8 morbidly obese patients a total body weight higher than 170 kg undergoing laparoscopic banding, laparoscopic sleeve gastrectomy or gastric bypass surgery, with a Body Mass Index > 40 kg/m2, 18-60 year old and American Society of Anaesthesiologists (ASA) physical status II to III.
Exclusion criteria
Exclusion criteria: Epilepsy, pregnancy, breastfeeding and known allergy for propofol, nadroparin, egg lecithin or soy bean oil.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic parameters of propofol in patients with a total body weight higher than 170 kg: clearance, intercompartmental clearance, volume of central compartment and volume of peripheral compartment. Pharmacodynamic parameters of nadroparin using anti-Xa levels in patients with a total body weight higher than 170 kg: clearance, intercompartmental clearance, volume of central compartment and volume of peripheral compartment, absorption rate constant, transit rate constant. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacodynamic parameters of propofol in patients with a total body weight higher than 170 kg; time to induction of anaesthesia (stop counting, eyelash reflex, quality of anaesthesia, corresponding dose required for induction of anaesthesia for both induction doses), EC50 using BIS, required doses of propofol during maintenance of anaesthesia, wake-up time. The occurrence of bleedings or thrombotic events in patients with a total body weight higher than 170 kg. Cardiac output records during surgery, measured by the NICOM® (Cheetah Medical) and Vigileo (Edwards Lifesciences) monitor | — |
Countries
Netherlands
Outcome results
None listed